Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Choline metabolism in malignant transformation.

Glunde K, Bhujwalla ZM, Ronen SM.

Nat Rev Cancer. 2011 Nov 17;11(12):835-48. doi: 10.1038/nrc3162. Review.

2.

Choline metabolism in cancer: implications for diagnosis and therapy.

Glunde K, Jacobs MA, Bhujwalla ZM.

Expert Rev Mol Diagn. 2006 Nov;6(6):821-9. Review.

PMID:
17140369
3.

Choline metabolism-based molecular diagnosis of cancer: an update.

Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwalla ZM.

Expert Rev Mol Diagn. 2015 Jun;15(6):735-47. doi: 10.1586/14737159.2015.1039515. Epub 2015 Apr 28. Review.

4.

Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

Glunde K, Serkova NJ.

Pharmacogenomics. 2006 Oct;7(7):1109-23. Review.

PMID:
17054420
5.

Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.

Glunde K, Jie C, Bhujwalla ZM.

Cancer Res. 2004 Jun 15;64(12):4270-6.

6.

Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.

Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, Gillies RJ.

NMR Biomed. 2009 Jan;22(1):114-27. doi: 10.1002/nbm.1318.

8.

MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Glunde K, Jiang L, Moestue SA, Gribbestad IS.

NMR Biomed. 2011 Jul;24(6):673-90. doi: 10.1002/nbm.1751. Review.

9.

Targeting Phospholipid Metabolism in Cancer.

Cheng M, Bhujwalla ZM, Glunde K.

Front Oncol. 2016 Dec 27;6:266. doi: 10.3389/fonc.2016.00266. eCollection 2016. Review.

10.

Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions.

Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM.

Mol Pharm. 2006 Sep-Oct;3(5):496-506. Review.

PMID:
17009848
12.

Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway.

Trousil S, Lee P, Pinato DJ, Ellis JK, Dina R, Aboagye EO, Keun HC, Sharma R.

Cancer Res. 2014 Dec 1;74(23):6867-77. doi: 10.1158/0008-5472.CAN-13-2409. Epub 2014 Sep 29.

13.
14.

Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.

Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO.

Br J Cancer. 2010 Jan 5;102(1):1-7. doi: 10.1038/sj.bjc.6605457. Epub 2009 Nov 24. Review.

15.

Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents.

Beloueche-Babari M, Workman P, Leach MO.

Cell Cycle. 2011 Sep 1;10(17):2883-93. Epub 2011 Sep 1. Review.

PMID:
21857160
16.

Choline phospholipid metabolism: a target in cancer cells?

Ackerstaff E, Glunde K, Bhujwalla ZM.

J Cell Biochem. 2003 Oct 15;90(3):525-33. Review.

PMID:
14523987
17.

Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy.

Inazu M.

Biopharm Drug Dispos. 2014 Nov;35(8):431-49. doi: 10.1002/bdd.1892. Epub 2014 Feb 27. Review.

PMID:
24532461
18.

Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.

Mignion L, Danhier P, Magat J, Porporato PE, Masquelier J, Gregoire V, Muccioli GG, Sonveaux P, Gallez B, Jordan BF.

Int J Cancer. 2016 Apr 15;138(8):2043-9. doi: 10.1002/ijc.29932. Epub 2015 Dec 9.

19.

HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.

Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM.

PLoS One. 2013 Apr 23;8(4):e62610. doi: 10.1371/journal.pone.0062610. Print 2013.

20.

Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis.

Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H.

Cancer Res. 2002 Apr 1;62(7):1966-70.

Supplemental Content

Support Center